BWX Technologies, Inc. (NYSE:BWXT) to Issue $0.27 Quarterly Dividend

BWX Technologies, Inc. (NYSE:BWXT) announced a quarterly dividend on Wednesday, April 29th. Stockholders of record on Tuesday, May 19th will be given a dividend of 0.27 per share by the technology company on Friday, June 5th. This represents a c) dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Tuesday, May 19th.

BWX Technologies has raised its dividend by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 2 years. BWX Technologies has a payout ratio of 27.6% meaning its dividend is sufficiently covered by earnings. Analysts expect BWX Technologies to earn $5.20 per share next year, which means the company should continue to be able to cover its $1.08 annual dividend with an expected future payout ratio of 20.8%.

BWX Technologies Stock Down 3.1%

BWX Technologies stock opened at $204.48 on Friday. The company has a debt-to-equity ratio of 1.58, a current ratio of 2.40 and a quick ratio of 2.33. The stock has a market capitalization of $18.73 billion, a price-to-earnings ratio of 54.68, a PEG ratio of 3.37 and a beta of 0.78. BWX Technologies has a 1-year low of $106.22 and a 1-year high of $241.82. The business has a fifty day moving average price of $212.76 and a 200-day moving average price of $199.93.

BWX Technologies (NYSE:BWXT) last posted its quarterly earnings data on Monday, May 4th. The technology company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $860.22 million during the quarter, compared to analysts’ expectations of $837.47 million. BWX Technologies had a return on equity of 31.33% and a net margin of 10.20%.The business’s quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.91 EPS. BWX Technologies has set its FY 2026 guidance at 4.600-4.750 EPS. Equities research analysts forecast that BWX Technologies will post 4.71 EPS for the current fiscal year.

Analyst Ratings Changes

BWXT has been the subject of a number of recent analyst reports. Wells Fargo & Company initiated coverage on BWX Technologies in a research report on Wednesday, April 1st. They issued an “underweight” rating and a $200.00 price objective for the company. Weiss Ratings raised BWX Technologies from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft raised BWX Technologies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $205.00 to $255.00 in a research report on Friday. BTIG Research raised their price objective on BWX Technologies from $225.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, TD Cowen initiated coverage on BWX Technologies in a research report on Thursday, March 12th. They issued a “buy” rating and a $230.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $222.96.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.